OAKLAND PARK, FL--(Marketwired - October 28, 2014) - Caribbean International Holdings, Inc. (PINKSHEETS: CIHN), announces a market update on many positive fronts. CIHN is excited to announce that it has applied to FINRA to change the Company's name to Biostem Technologies, Inc. to more fully align with the Company's core business focus. The name change will not be effective until FINRA gives its approval. Furthermore, and as previously announced, a private investment group, J3 Financial, has acquired a controlling interest in CIHN.
Since acquiring control, management and J3 Financial have done a tremendous amount of restructuring in order to start to aggressively build this emerging company.
A company spokesperson commented, "We appreciate the patience from our shareholders through this recent transition and quiet time, however it was much needed in order to be much more successful going forward as we launch many new and great things."
The Company's new corporate office is located at:
4749 N.E. 11th Ave
Oakland Park, FL 33334
On another note the company is happy to announce that Jason Matuszewski was recently appointed as the President and Secretary of CIHN and the Company has appointed Mark Farber MD, PhD, MS as its new CEO. Mark Farber MD, PhD, MS Received Degrees From Brown University and SUNY; During his time at Harvard Medical School he developed bioreactor designs for stem cell based tissue engineered heart valves.
Jason Matuszewski, the President of CIHN stated, "Our web development team is just now finishing the final touches to our new corporate website which will be http://www.biostemtech.com. We look to announce and release this new corporate website for CIHN by Mid-November 2014. This user-friendly corporate portal will display a wide variety of details and news on Biostem Technologies, Inc., our company, both current and ongoing. We have already started to accomplish so much in such little time in the ever so fast growing Stem Cell marketplace."
We are also happy to announce that the Board has had many progressive meetings with Rafael Gonzalez, Ph.D., the senior member on the Company's Advisory Board. The Company will be unveiling more about these positive meetings and unfolding events in the near term. Dr. Gonzalez is currently responsible for the development of clinical stem cell applications for several disease/trauma states for DaVinci Biosciences as their VP of Research & Development. Dr. Gonzalez is also responsible for the design and execution of all pre-clinical and clinical experiments for DaVinci Biosciences involving adult (bone marrow, menstrual blood, adipose) and pre-natal stem cells (neural, bone marrow, liver, gonadal).
Dr. Gonzalez is dedicated to helping us achieve our goals of bringing science and medicine together to improve the well-being and future of patients. His knowledge in stem cell research and development as well as implementing standard operating procedures will be a tremendous benefit to our Company. In addition to his experience in stem cell culture and biology from human embryonic, pre-natal and adult sources, he has extensive knowledge in degenerative disorders involving the spinal cord.
The Company spokesperson also said that the Company feels it is important in today's market to keep its shareholders fully abreast of ongoing events and news. The Company plans on keeping the market up to date in order to remain fully transparent with the Company's current and/or potential future shareholders and the market at large.
About Caribbean International Holdings, Inc. (CIHN):
Caribbean International Holdings, Inc. is a holding company for Regenerative Bio Science, Inc. ("RBSI"). The Company subsidiary RBSI is focused on helping individuals protect and ensure their future quality of life through Adult Stem Cell Incubation and the practice of regenerative medicine in the United States and the Dominican Republic. RBSI's mission is not only to allow patients to store their Stem Cells for future use, but also perform patient funded stem cell therapies from sports injuries to degenerative diseases such as MS, Arthritis, Degenerative Heart Diseases, Diabetes and a host of experimental therapies in the brain trauma disease sector including CTE. The goal is to become a global leader in establishing protocols that can be patented and utilized to heal patients around the world.
Adult stem cells work as the repairmen of the body by replenishing and regenerating damaged tissues and cells. Certain conditions have shown marked improvement when treated with adult stem cells taken from the patient's own body. Regenerative Bioscience is a revolution in healthcare using a patient's own adult stem cells.
Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "future," "plan" or "planned," "expects," or "projected." These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and additional risks factors as discussed in reports filed by the company with the Securities and Exchange Commission, which are available on at http://www.sec.gov.